Patient Organization

- Health at Bayer
-
Pharmaceuticals
- Treatments & Therapies
- Innovation & Technologies
- Sustainability
- Transparency
- News & Stories
- Clinical Trials Explorer
- Transparency Policy
- Personal Health
- Report a Side Effect
- Medical Counterfeits
The patient comes first
For Bayer, one of the world's leading specialty pharmaceutical companies, patients' health always comes first. Exchanging ideas and information with patient organizations on the basis of mutual trust is an important component of our work.
Such cooperation helps us to understand the needs of patients as they come to terms with their illness. This enables us to gear our research and development to these needs and to continue working on improved, new drugs and therapies.
Bayer cooperates with patient organizations in all kinds of therapeutic areas. We attach great importance to transparency in this context and protect the independence of our cooperation partners.
Our principles
Cooperation between Bayer and patient organizations is based on the following principles.
- In order to provide patients with quality medical healthcare, a partnership with a patient organization pursues a specific objective concentrating on one or more of the following areas:
- raising awareness for certain diseases by improving diagnostic possibilities and preventive measures, knowing the patients' prospects and needs,
- understanding diseases and making sure that patients receive the best medical treatment available,
- improving the information provided to the patients,
- supporting medical innovations.
- Bayer and the patient organizations comply with international and national laws and regulations.
- Cooperation with a patient organization should neither influence decisions on a therapy nor promote or support specific therapies.
- Bayer respects the neutrality and independence of patient organizations. Cooperation is based on a partnership between equals in which transparency and clarity are fundamental principles. This is why we also provide information on the extent and nature of support.
Overview of cooperation with patient organizations in Europe in 2021
The following is a list of patient organizations with which Bayer and its affiliated companies in Europe cooperated in 2021.
Headquarters:
Bayer Company |
Bayer AG |
Contract date |
2021 |
Amount |
50.000 EUR |
Purpose of interaction |
Supporting the development and implementation of national stroke plans through the Stroke Action Plan for Europe (SAPE) |
Bayer Company |
Bayer AG |
Contract date |
28.09.2021 |
Amount |
10.000 EUR |
Purpose of interaction |
Bronze membership in organization to attend conference and have logo on website; Access to Patient Advisory Network for study-related survey |
Bayer Company |
Bayer AG |
Contract date |
6/2021 |
Amount |
15.000 EUR |
Purpose of interaction |
One year Diamond membership for Patient engagement activities |
Bayer Company |
Bayer AG |
Contract date |
6/2021 |
Amount |
1.890 EUR |
Purpose of interaction |
Patient recruitment for podcast series regarding regenerative medicine discussions |
Bayer Company |
Bayer AG |
Contract date |
12/2021 |
Amount |
46.480 EUR |
Purpose of interaction |
Four Patient Engagement symposiums, resource + manual |
Bayer Company |
Bayer AG |
Contract date |
15.06.2020 |
Amount |
25.000 EUR |
Purpose of interaction |
World Scleroderma Day Sponsorship |
Bayer Company |
Bayer AG |
Contract date |
03.07.2021 |
Amount |
75.000 EUR |
Purpose of interaction |
Sponsorship of Activities of PHA Europe |
Bayer Company |
BCC AG |
Contract date |
24.09.2021 |
Amount |
40.000 EUR |
Purpose of interaction |
Annual Sponsorship |
Bayer Company |
BCC AG |
Contract date |
27.01.2021 |
Amount |
5.000 GBP |
Purpose of |
Annual Sponsorship |
Bayer Company |
BCC AG |
Contract date |
26.05.2021 |
Amount |
35.000 EUR |
Purpose of interaction |
Sponsorship Agreement EHC 2021 Annual Conference |
Bayer Company |
BCC AG |
Contract date |
25.02.2021 |
Amount |
30.000 EUR |
Purpose of interaction |
Platinum CGP membership |
Bayer Company |
BCC AG |
Contract date |
01.03.2021 |
Amount |
598,50 EUR |
Purpose of interaction |
EU Patient Council / honorarium |
Europe:
Reports can be received from
UAB Bayer Baltic Republics (Estonia, Latvia, Lithuania)
Alina Tikuišiene MD
Zirmunu str. 68A
LT-09124 Vilnius/Lithunia
Reports can be received from
UAB Bayer Baltic Republics (Estonia, Latvia, Lithuania)
Alina Tikuišiene MD
Zirmunu str. 68A
LT-09124 Vilnius/Lithunia
Reports can be received from
Bayer AB- Bayer Scandinavia
Iina Wargh
Gustav III:s Boulevard 56
169 26 Solna
Reports can be received from
SC Bayer SRL
Bayer Pharmaceuticals Division
Sos. Pipera nr. 42., Sector 2
NUSCO Tower fl. 1,16,17
020112, Bucharest
Romania
Reports can be received from
Bayer Pharma d.o.o.
Jelena Tokanovic
Omladinskih brigada 88b
Belgrade
Reports can be received from
Bayer d.o.o.
Lucija Zlodi Gosnik
Bravnicarjeva 13
1000 Ljubljana